drugset / Trial / NCT00973323
BAY59-7939 Japanese in Atrial Fibrillation (2nd)
RandomizedParallel-groupOpen-labelPrevention
Summary
This study was a randomized, parallel group, open label trial using warfarin as comparator. Pharmacokinetics (PK) and pharmacodynamics (PD) were investigated only in BAY59-7939 groups (originally described in Japanese).
Timeline
- Start
- 2005-09
- Primary completion
- —
- Completion
- 2006-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivaroxaban | Other / unclassified | 2.5 mg | — |
| Subject | Rivaroxaban | Other / unclassified | 5 mg | — |
| Subject | Rivaroxaban | Other / unclassified | 10 mg | — |
| Comparator | Warfarin | Small molecule | — | — |